|
Lupin Ltd has reported a growth of 37.4% in net profit during the third quarter ended December 31, 2025, at Rs. 1,180.5 crore as compared to Rs. 858.9 crore in the same period of previous fiscal year.
Total revenue from operations grew 24.3% to Rs. 7,167.5 crore during the quarter, as against Rs. 5,767.8 crore during the same period a year ago. Investment in R&D for the quarter was Rs. 535.2 crore, which is 7.5% of sales.
Nilesh Gupta, managing director, Lupin Limited said “We are happy to deliver another quarter of strong growth led by our highest ever quarterly sales in the US and double-digit growth in India and all other regions. We are on track to deliver a strong close to FY26."
Sales in US, which accounts to 44% of the company's global sales, grew 54% YoY at Rs. 3,113.2 crore compared to Rs. 2,022.1 crore a year ago, while India (29% of global sales) sales grew 5.6% to Rs. 2,038.7 crore from Rs. 1,930.5 crore. Sales in the other developed markets (11% of global sales) grew 10.8% to Rs. 812.1 crore, while emerging markets (13% of global sales) reported 42.4% growth at Rs. 917 crore during the quarter ended December 31.
The formulations business grew 29.1% to Rs. 6,881 crore during the period, while active pharmaceutical ingredients business grew 26.4% to Rs. 7,100.5 crore as compared to the same period of previous fiscal year.
The company received 1 ANDA approvals from the US FDA, and launched 3 products in the quarter in the US. The Company now has 149 generic products in the US market.
Cumulative ANDA filings with the US FDA stand at 431 as of December 31, 2025, with the company having received 341 approvals to date. The Company now has 52 First-to-File (FTF) filings including 22 exclusive FTF opportunities. Cumulative US DMF filings stand at 93 as of December 31, 2025, said the company.
|